UnitedHealth Group cuts profit forecasts due to higher Medicare Advantage care costs and lower coding revenue, highlighting challenges in Medicare Advantage management and insurance financials.
U.S. commercial insurance market experiences stability with excess casualty capacity shifts amid evolving risks and regulatory challenges, industry leaders report at Riskworld.
U.S. life insurers are increasing investments in residential mortgages, shifting from commercial loans, impacting portfolio composition, credit quality, and risk metrics.
Phoenix man’s BMW repair delayed 4 months due to insurance payment issues with Cox Communications provider. Highlights challenges in auto claims and insurer payment processes.
The DOJ sued SelectQuote and major insurers over Medicare Advantage plan kickbacks, leading to a 19% stock drop. This case highlights key compliance risks in broker compensation and Medicare Advantage enrollment.
In 2023, Fresno County homeowners in California face increasing insurance non-renewals and premiums due to market challenges and regulatory developments. Learn about policy renewal conditions, aerial inspections, and the state's sustainable insurance strategy.
Liberty Mutual reports $1B Q1 2025 net income, down 33%, impacted by $1.8B catastrophe losses from California wildfires. Underwriting improvements lowered the underlying combined ratio to 81.9. Net written premiums fell in U.S. retail markets but rose 7.5% in Global Risk Solutions.
Levi & Korsinsky LLP has commenced an investigation into CVS Health following DOJ allegations of illegal kickbacks related to Medicare Advantage plan enrollments, highlighting increased regulatory focus on insurance brokerage compliance.
Arizona mandates independent medical director reviews for health insurer claims denials and prior authorizations based on medical necessity, effective June 2026.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
